|
2022 Journal Article Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: Subgroup analysis by programmed death ligand-1 combined positive scoreBurtness, Barbara, Rischin, Danny, Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro Jr, Gilberto, Psyrri, Amanda, Brana, Irene, Basté, Neus, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesia, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Wan Ishak, Wan Zamaniah, Ge, Joy, Swaby, Ramona F., Gumuscu, Burak and Harrington, Kevin (2022). Pembrolizumab alone or with chemotherapy for recurrent/metastatic head and neck squamous cell carcinoma in KEYNOTE-048: Subgroup analysis by programmed death ligand-1 combined positive score. Journal of Clinical Oncology, 40 (21), 2321-2332. doi: 10.1200/jco.21.02198 |
|
2022 Journal Article Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancerKapeleris, Joanna, Bark, Juliana Müller, Ranjit, Shanon, Irwin, Darryl, Hartel, Gunter, Warkiani, Majid Ebrahimi, Leo, Paul, O’Leary, Connor, Ladwa, Rahul, O'Byrne, Kenneth, Hughes, Brett G.M. and Punyadeera, Chamindie (2022). Prognostic value of integrating circulating tumour cells and cell-free DNA in non-small cell lung cancer. Heliyon, 8 (7) e09971, 1-9. doi: 10.1016/j.heliyon.2022.e09971 |
|
2022 Journal Article Application of circulating tumour cells to predict response to treatment in head and neck cancerZhang, Xi, Ekanayake Weeramange, Chameera, Hughes, Brett G. M., Vasani, Sarju, Liu, Zhen Yu, Warkiani, Majid Ebrahimi, Hartel, Gunter, Ladwa, Rahul, Thiery, Jean Paul, Kenny, Liz and Punyadeera, Chamindie (2022). Application of circulating tumour cells to predict response to treatment in head and neck cancer. Cellular Oncology, 45 (4), 1-13. doi: 10.1007/s13402-022-00681-w |
|
2022 Journal Article A randomized, double-blind noninferiority study to evaluate the efficacy of the cabozantinib tablet at 60 mg per day compared with the cabozantinib capsule at 140 mg per day in patients with progressive, metastatic medullary thyroid cancerCapdevila, Jaume, Klochikhin, Arkadiy, Leboulleux, Sophie, Isaev, Pavel, Badiu, Corin, Robinson, Bruce, Hughes, Brett G.M., Keam, Bhumsuk, Parnis, Francis, Elisei, Rossella, Gajate, Pablo, Gan, Hui K., Kapiteijn, Ellen, Locati, Laura, Mangeshkar, Milan, Faoro, Leonardo, Krajewska, Jolanta and Jarzab, Barbara (2022). A randomized, double-blind noninferiority study to evaluate the efficacy of the cabozantinib tablet at 60 mg per day compared with the cabozantinib capsule at 140 mg per day in patients with progressive, metastatic medullary thyroid cancer. Thyroid, 32 (5), 515-524. doi: 10.1089/thy.2022.0027 |
|
2022 Journal Article Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell CarcinomasSadeghirad, Habib, Monkman, James, Mehdi, Ahmed M., Ladwa, Rahul, O’Byrne, Ken, Hughes, Brett G. M. and Kulasinghe, Arutha (2022). Dissecting Tissue Compartment-Specific Protein Signatures in Primary and Metastatic Oropharyngeal Squamous Cell Carcinomas. Frontiers in Immunology, 13 895513, 1-11. doi: 10.3389/fimmu.2022.895513 |
|
2022 Journal Article Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048Rischin, Danny, Harrington, Kevin J., Greil, Richard, Soulières, Denis, Tahara, Makoto, de Castro Jr, Gilberto, Psyrri, Amanda, Braña, Irene, Neupane, Prakash, Bratland, Åse, Fuereder, Thorsten, Hughes, Brett G.M., Mesía, Ricard, Ngamphaiboon, Nuttapong, Rordorf, Tamara, Ishak, Wan Zamaniah Wan, Hong, Ruey-Long, Mendoza, René Gonzalez, Jia, Liyi, Chirovsky, Diana, Norquist, Josephine, Jin, Fan and Burtness, Barbara (2022). Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncology, 128 105815, 1-12. doi: 10.1016/j.oraloncology.2022.105815 |
|
2022 Journal Article The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic reviewEdwards, Anna, Brown, Teresa, Hughes, Brett G. M. and Bauer, Judy (2022). The changing face of head and neck cancer: are patients with human papillomavirus-positive disease at greater nutritional risk? A systematic review. Supportive Care in Cancer, 30 (9), 7191-7204. doi: 10.1007/s00520-022-07056-9 |
|
2022 Journal Article A randomized study of Lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancerBrose, Marcia S., Panaseykin, Yury, Konda, Bhavana, de la Fouchardiere, Christelle, Hughes, Brett G. M., Gianoukakis, Andrew G., Joo Park, Young, Romanov, Ilia, Krzyzanowska, Monika K., Leboulleux, Sophie, Binder, Terri A., Dutcus, Corina, Xie, Ran and Taylor, Matthew H. (2022). A randomized study of Lenvatinib 18 mg vs 24 mg in patients with radioiodine-refractory differentiated thyroid cancer. Journal of Clinical Endocrinology and Metabolism, 107 (3), 776-787. doi: 10.1210/clinem/dgab731 |
|
2022 Journal Article Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatmentAhern, Elizabeth, Brown, Teresa E, Campbell, Louise, Hughes, Brett G. M., Banks, Merrilyn D., Lin, Charles Y., Kenny, Lizbeth M. and Bauer, Judith D. (2022). Impact of sarcopenia and myosteatosis on survival outcomes for patients with head and neck cancer undergoing curative-intent treatment. British Journal of Nutrition, 129 (3) PII S0007114522000435, 1-25. doi: 10.1017/S0007114522000435 |
|
2022 Journal Article Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trialPeters, S., Pujol, J. L., Dafni, U., Dómine, M., Popat, S., Reck, M., Andrade, J., Becker, A., Moro-Sibilot, D., Curioni-Fontecedro, A., Molinier, O., Nackaerts, K., Insa Mollá, A., Gervais, R., López Vivanco, G., Madelaine, J., Mazieres, J., Faehling, M., Griesinger, F., Majem, M., González Larriba, J. L., Provencio Pulla, M., Vervita, K., Roschitzki-Voser, H., Ruepp, B., Mitchell, P., Stahel, R. A., Le Pechoux, C., De Ruysscher, D. ... Califano, R. (2022). Consolidation nivolumab and ipilimumab versus observation in limited-disease small-cell lung cancer after chemo-radiotherapy – results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial. Annals of Oncology, 33 (1), 67-79. doi: 10.1016/j.annonc.2021.09.011 |
|
2022 Journal Article Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trialKok, Peey Sei, Forde, Patrick M., Hughes, Brett, Sun, Zhuoxin, Brown, Chris, Ramalingam, Suresh, Cook, Alistair, Lesterhuis, Willem Joost, Yip, Sonia, O'Byrne, Ken, Pavlakis, Nick, Brahmer, Julie, Anagnostou, Valsamo, Ford, Kate, Fitzpatrick, Karen, Bricker, Alison, Cummins, Michelle M., Stockler, Martin and Nowak, Anna K. (2022). Protocol of DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma-a phase 3 randomised trial. BMJ Open, 12 (1) e057663, e057663. doi: 10.1136/bmjopen-2021-057663 |
|
2022 Journal Article Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008))Hughes, B. G.M., Munoz-Couselo, E., Mortier, L., Bratland, , Gutzmer, R., Roshdy, O., González Mendoza, R., Schachter, J., Arance, A., Grange, F., Meyer, N., Joshi, A., Billan, S., Zhang, P., Gumuscu, B., Swaby, R. F. and Grob, J. J. (2022). Corrigendum to ‘Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial: [Annals of Oncology Volume 32, Issue 10, October 2021, Pages 1276-1285] (Annals of Oncology (2021) 32(10) (1276–1285), (S0923753421021864), (10.1016/j.annonc.2021.07.008)). Annals of Oncology, 33 (8), 853-853. doi: 10.1016/j.annonc.2022.05.517 |
|
2022 Journal Article Understanding the tumor microenvironment in head and neck squamous cell carcinomaRad, Habib Sadeghi, Shiravand, Yavar, Radfar, Payar, Ladwa, Rahul, Perry, Chris, Han, Xiaoyuan, Warkiani, Majid Ebrahimi, Adams, Mark N., Hughes, Brett G.M., O'Byrne, Ken and Kulasinghe, Arutha (2022). Understanding the tumor microenvironment in head and neck squamous cell carcinoma. Clinical & Translational Immunology, 11 (6) e1397, e1397. doi: 10.1002/cti2.1397 |
|
2021 Journal Article Evaluation of a novel pre‐treatment model of nutrition care for patients with head and neck cancer receiving chemoradiotherapyBlake, Claire, Edwards, Anna, Treleaven, Elise, Brown, Teresa, Hughes, Brett, Lin, Charles, Kenny, Lizbeth, Banks, Merrilyn and Bauer, Judy (2021). Evaluation of a novel pre‐treatment model of nutrition care for patients with head and neck cancer receiving chemoradiotherapy. Nutrition and Dietetics, 79 (2), 206-216. doi: 10.1111/1747-0080.12714 |
|
2021 Journal Article A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinomaLin, Charles, Ballah, Trishna, Nottage, Michelle, Hay, Karen, Chua, Benjamin, Kenny, Lizbeth, Thomas, Paul, Teng, Michele, Keller, Jacqui, Le, Trang, Edmunds, Jennifer and Hughes, Brett (2021). A prospective study investigating the efficacy and toxicity of definitive ChemoRadiation and ImmunOtherapy (CRIO) in locally and/or regionally advanced unresectable cutaneous squamous cell carcinoma. Radiation Oncology, 16 (1) 69, 1-13. doi: 10.1186/s13014-021-01795-5 |
|
2021 Journal Article Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group StudyRischin, Danny, King, Madeleine, Kenny, Lizbeth, Porceddu, Sandro, Wratten, Christopher, Macann, Andrew, Jackson, James E., Bressel, Mathias, Herschtal, Alan, Fisher, Richard, Fua, Tsien, Lin, Charles, Liu, Chen, Hughes, Brett G.M., McGrath, Margaret, McDowell, Lachlan and Corry, June (2021). Randomized trial of radiation therapy with weekly cisplatin or cetuximab in low-risk HPV-associated oropharyngeal cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group Study. International Journal of Radiation: Oncology - Biology - Physics, 111 (4), 876-886. doi: 10.1016/j.ijrobp.2021.04.015 |
|
2021 Journal Article The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC)Kulasinghe, Arutha, O'Leary, Connor, Monkman, James, Bharti, Vandhana, Irwin, Darryl, Dutta, Sanjay, Richard, Derek J., Hughes, Brett, Ladwa, Rahul and O'Byrne, Ken (2021). The identification of circulating tumour DNA using MassARRAY technology in non-small-cell lung cancer (NSCLC). Lung Cancer, 160, 73-77. doi: 10.1016/j.lungcan.2021.08.005 |
|
2021 Journal Article Health-related quality of life of patients with recurrent or metastatic cutaneous squamous cell carcinoma treated with Pembrolizumab in KEYNOTE-629Hughes, Brett G. M., Mendoza, Rene Gonzalez, Basset-Seguin, Nicole, Vornicova, Olga, Schachter, Jacob, Joshi, Abhishek, Meyer, Nicolas, Grange, Florent, Piulats, Josep M., Bauman, Jessica R., Chirovsky, Diana, Zhang, Pingye, Gumuscu, Burak, Swaby, Ramona F. and Grob, Jean-Jacques (2021). Health-related quality of life of patients with recurrent or metastatic cutaneous squamous cell carcinoma treated with Pembrolizumab in KEYNOTE-629. Dermatology and Therapy, 11 (5), 1777-1790. doi: 10.1007/s13555-021-00598-6 |
|
2021 Journal Article Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysisRischin, Danny, Khushalani, Nikhil I., Schmults, Chrysalyne D., Guminski, Alexander, Chang, Anne Lynn S., Lewis, Karl D., Lim, Annette M., Hernandez-Aya, Leonel, Hughes, Brett G. M., Schadendorf, DIrk, Hauschild, Axel, Thai, Alesha A., Stankevich, Elizabeth, Booth, Jocelyn, Yoo, Suk-Young, Li, Siyu, Chen, Zhen, Okoye, Emmanuel, Chen, Chieh-I, Mastey, Vera, Sasane, Medha, Lowy, Israel, Fury, Matthew G. and Migden, Michael R. (2021). Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. Journal for ImmunoTherapy of Cancer, 9 (8) e002757, e002757. doi: 10.1136/jitc-2021-002757 |
|
2021 Journal Article Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trialHughes, B. G. M., Munoz-Couselo, E., Mortier, L., Bratland, Å., Gutzmer, R., Roshdy, O., González Mendoza, R., Schachter, J., Arance, A., Grange, F., Meyer, N., Joshi, A., Billan, S., Zhang, P., Gumuscu, B., Swaby, R. F. and Grob, J.-J. (2021). Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial. Annals of Oncology, 32 (10), 1276-1285. doi: 10.1016/j.annonc.2021.07.008 |
